{"ticker": {"uuid": "1c611df5-7009-405a-a224-8b2fa7373100", "symbol": "HRTX", "name": "Heron Therapeuti", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Report - Results, Call & Slides", "summary": "Heron Therapeutics (HRTX) reported strong Q1 2024 earnings, beating both EPS and revenue expectations. The company recorded an actual EPS of -$0.02 against a consensus of -$0.07, and revenue of $34.67 million, surpassing the expected $32.98 million. The report also highlights a s", "url": "https://www.tipranks.com/stocks/hrtx/earnings/q1-2024-report", "source_name": "TipRanks", "published_at": "2026-07-17T06:42:03", "published_display": "17 Jul 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of \"Hold\" from Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQ19rV0o1LVBOUEt4VW5qS1ZzN29GWEs4NS1jbE11eVgwNW5PQ1JtQllsU21lZEFXbmNSaGdwRFd2M1RaeVZOSWlTRmZEMmFUUTdPS1EzUXVpY1ZCWkRjR0JXd1NjeHpiZ0s5S0pFWnVzUDlVX3JDMUVRLUlua0Vtb2RGeG82U0wyc0ptdlBLZU8taFZ3Vi1MSUtCSWlpdHJNTElLQnFYX1ZoUGc3ajhsc3RiYVhIcnNZN29hZXE2M1ZTSjhfZHZZQUtaLXNHRkxpQWVR?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T22:41:15+00:00", "published_display": "12 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics updates investors on business progress as development pipeline remains the key va", "summary": "Heron Therapeutics is progressing its drug portfolio, focusing on operational execution and a long-term strategy for treatments in oncology support and pain management. The company's stock valuation is closely tied to its clinical development pipeline, regulatory milestones, and ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-updates-investors-on-business-progress-as-development/69716306", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:24:06", "published_display": "07 Jul 2026 17:24", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRTX - Heron Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of Heron Therapeutics Inc. (HRTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider and institutional ownership, and short inter", "url": "https://finviz.com/stock?t=HRTX&p=d&ty=oc&r=y1&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-05T15:11:34", "published_display": "05 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?", "summary": "Heron Therapeutics (HRTX) faces a setback after a U.S. District Court ruled against it in Cinvanti patent litigation, leading H.C. Wainwright to lower its price target. The company plans to appeal the decision, asserting confidence in its legal arguments and intellectual property", "url": "https://www.insidermonkey.com/blog/is-heron-therapeutics-inc-hrtx-stock-a-recovery-opportunity-after-cinvanti-patent-court-ruling-1792090/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:29", "published_display": "30 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Heron Therapeutics received a notice from Nasdaq on June 25, 2026, stating that its common shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company has 180 days, until December 22, 2026, to regain compliance by maintaining a cl", "url": "https://www.tradingview.com/news/tradingview:0cc9053fbce63:0-heron-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:55", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision", "summary": "Heron Therapeutics (HRTX) has seen its analyst fair value estimate cut from US$4.75 to US$3.00 per share following a Cinvanti patent decision that invalidated claims on two patents. This revision reflects legal risks, potential generic competition for Cinvanti (which accounts for", "url": "https://finance.yahoo.com/markets/stocks/articles/heron-therapeutics-hrtx-stock-sees-230609790.html", "source_name": "Market source", "published_at": "2026-06-27T19:06:00", "published_display": "27 Jun 2026 19:06", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification", "summary": "Heron Therapeutics announced it received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement. The company has 180 calendar days, until December 23, 2024, to regain compliance, with a possible extension for another 180 days. Heron's common stoc", "url": "https://www.moomoo.com/news/post/72101837/heron-therapeutics-receives-nasdaq-minimum-bid-price-notification", "source_name": "Moomoo", "published_at": "2026-06-26T20:10:08", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P", "summary": "This article provides a statement of changes in beneficial ownership of securities for Officer Forbes William P at Heron Therapeutics. The document details the modifications in his holdings.", "url": "https://www.moomoo.com/news/notice/306995508/heron-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T09:09:01", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX)", "summary": "This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting pa", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:01", "published_display": "26 Jun 2026 07:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc Actuals & Estimates (BX:AXD2)", "summary": "This article provides an overview of Heron Therapeutics Inc. (BX:AXD2) stock, including its current price, market capitalization, analyst forecasts, and historical highs and lows. It also details the company's recent financial performance, such as earnings per share and revenue, ", "url": "https://www.tradingview.com/symbols/BX-AXD2/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T06:09:02", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Heron Therapeutics, Inc. \u2013 NASDAQ:HRTX", "summary": "This article provides financial data specifically regarding the enterprise value to revenue forward metric for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a stub or an entry on a financial data platform from TradingView, indicating that the value for this specific p", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:29", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price", "summary": "Heron Therapeutics (NASDAQ: HRTX) has received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, as its stock traded below this level for thirty consecutive days. The company has 180 calendar days, until December 22, 2026, to regain compl", "url": "https://www.stocktitan.net/sec-filings/HRTX/8-k-heron-therapeutics-inc-de-reports-material-event-6551f85a8267.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:40:23", "published_display": "25 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Heron Therapeutics, Inc. \u2013 NASDAQ:HRTX", "summary": "This article provides financial data, specifically the \"Price to sales forward\" for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial snapshot from TradingView, offering a quick look at this metric, but without further details or analysis within the provided t", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:24", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Stock - long-term strategy under pressure after reverse split and Nasdaq warning", "summary": "Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nasdaq's minimum bid price requirements and receiving a Nasdaq listing deficiency notice. The company, focused on pain management and", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-stock-long-term-strategy-under-pressure-after-reverse/69592936", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T20:37:34", "published_display": "20 Jun 2026 20:37", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Heron Therapeutics Inc (HRTX) regarding its dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and that there is no historical data available for both dividend payments and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:35", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Heron Therapeutics Inc (HRTX) by business segment and region for the reported fiscal years, updated on April 6. It highlights that CINVANTI, SUSTOL, ZYNRELEF, and APONVIE are the primary revenue contributors, with CINVANTI ac", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:35", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting", "summary": "Heron Therapeutics (NASDAQ:HRTX) stockholders approved all six proposals at their 2026 Annual Meeting on June 11, including the election of seven directors and the ratification of their accounting firm. Key amendments to equity incentive and employee stock purchase plans were als", "url": "https://m.uk.investing.com/news/sec-filings/heron-therapeutics-stockholders-approve-director-slate-and-plan-amendments-at-annual-meeting-93CH-4731345?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T19:39:53", "published_display": "17 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Stock - Shareholders back equity plans and tax measure at 2026 meeting", "summary": "Heron Therapeutics shareholders approved all proposals at their 2026 annual meeting, including significant increases to equity and employee stock purchase plans and a tax benefits preservation plan. This approval provides management with greater flexibility in using stock-based c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-stock-shareholders-back-equity-plans-and-tax-measure/69564649", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T16:10:33", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes", "summary": "Heron Therapeutics' EVP and CFO, Ira Duarte, engaged in routine equity compensation activity, exercising 12,500 restricted stock units on June 16, 2026. To cover tax obligations, Duarte disposed of 3,555 common shares at $0.38 per share. Following these transactions, Duarte direc", "url": "https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-78af11d266b6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T15:10:33", "published_display": "17 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Heron Therapeutics Inc (HRTX) has a current financial score of 7.51, ranking 112 out of 388 in its industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71M, and its net profit sa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:33", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis", "summary": "Heron Therapeutics Inc (HRTX) has a current valuation score of 8.03, ranking 178 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -2.11, significantly different from its recent high and low. Data for P/B, P/S, and P/CF ratios have not been d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:08", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Heron Therapeutics Inc (HRTX), evaluating its volatility, financial risk, and investment risk. The company's risk assessment score is 4.44, ranking 80 out of 388 in the Biotechnology & Medical Research industry, with a beta of 1.62 indi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:08", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com", "summary": "Heron Therapeutics stockholders approved all six proposals at their 2026 Annual Meeting, including the election of seven directors and the ratification of their accounting firm. They also approved executive compensation and two plan amendments related to equity incentives and emp", "url": "https://za.investing.com/news/sec-filings/heron-therapeutics-stockholders-approve-director-slate-and-plan-amendments-at-annual-meeting-93CH-4331283", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T20:39:32", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan", "summary": "Heron Therapeutics stockholders approved several key proposals at their 2026 Annual Meeting on June 11, 2026. This included electing seven directors, ratifying their auditor, and approving executive compensation on an advisory basis. Shareholders also significantly increased the ", "url": "https://www.stocktitan.net/sec-filings/HRTX/8-k-heron-therapeutics-inc-de-reports-material-event-b902ff6de2d8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:10:08", "published_display": "16 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)", "summary": "Heron Therapeutics faces a significant setback after a court ruled its Cinvanti patents invalid, jeopardizing its main revenue source. The growth of Zynrelef is insufficient to compensate for potential Cinvanti losses, while other products like Aponvie and Sustol have not met exp", "url": "https://seekingalpha.com/article/4913700-heron-therapeutics-in-a-tough-spot-after-cinvanti-court-loss-rating-downgrade", "source_name": "Seeking Alpha", "published_at": "2026-06-10T12:38:52", "published_display": "10 Jun 2026 12:38", "sentiment": "negative", "sentiment_pct": 5, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares", "summary": "Heron Therapeutics' EVP, William P. Forbes, exercised 12,500 restricted stock units (RSUs) into common shares on June 6, 2026, as part of his compensation, incurring no cash cost. Following this transaction, Forbes directly holds 221,611 common shares and 12,500 RSUs that will ve", "url": "https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-79edca4de4e0.html", "source_name": "Stock Titan", "published_at": "2026-06-08T14:39:45", "published_display": "08 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents", "summary": "Heron Therapeutics has announced its intention to appeal a U.S. District Court ruling that invalidated patents covering its CINVANTI drug. The company will pursue this appeal to the U.S. Court of Appeals for the Federal Circuit to protect its intellectual property amidst potentia", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2293053/heron-therapeutics-appeals-ruling-invalidating-cinvanti-patents/", "source_name": "The Globe and Mail", "published_at": "2026-06-03T23:39:45", "published_display": "03 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Says US Court Rules 2 Cinvanti Patent Claims 'Invalid'", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/heron-therapeutics-says-us-court-124355270.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:43:55+00:00", "published_display": "02 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics loses patent case over Cinvanti drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb3pjTmVJcC1LbkN5OG1qRG5ta1BCa3BBTFR3U1RCZDFnUVU2NnB5U3BiMUdVWFRWaWY0T2VWTDZGNU1CSVUzSThjdWhVcnk3aW05RmFnaFI0X29JQVRKbmRWVEYxZFVwbGE2c1NDTTItbVFNSG9mRGZMSXdiWGdQZDZkSjRWMGRvNWRxUVhXV1BiTVFoZ0JzOHpwQkF4ZXBud1VydWVUYlJCYWpOX2JxS0ZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOFRrWFZXZG5XSzJrSnJEZGZTUm92SGFyUEJ0OEhhZVVmNnhXY3VObUthZ2U3UnNMSFZYT2lpai1tVGdVYm1IR19mV283THZaaEoxMXBBa0xxUjk2RXItdmpFd21VQ0FYRTFSYVF0TGxobUtvc1I0ckp4bGplNk5NeDI3ZE9NMVFER2x1YzlWc0t2UUtOYWZ6ZEhMT1luakd1Ync?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOTWt2dXNmSW1kaXY3bjJEcmtFem9ROGFITDFrY2hDcjJrTFhET1FKWHBzRHl6bDdIcmc1Uk5PakxRbGhMeGUwVFlSOFItSGJoTXlJWkdrZzd0cktPeFdMVWpTemQxNklCbmwyYWx0aHM1SWlRenQ2dTVvSjNwTnRvdVROY1VkMDJzZzFHc1dacnJRSlluT2h0bllHWHpzZDVMS1ZjT1VB?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNbEVELTRWQTI5bmpiSDNrRnlMY0ZlX2lEOFZvT0VKOGhkSGRrSi1MNHN2N1kyVWZRQmlzYXZ2ZWN0M1h6YXhQSDU5ampwMGtIWnV3OEpOM3gwbFozLVdoMzJ5X19NSmhkLXkwRTVGdDc5dTNWam9SUGtaYjZiWTNPYlVkQTFtZ0JDcThxS1k5RWRfLTJCUnlhd3JaVlo4ZzFnZFRXZWM2RExTZFNmNEU0?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring a Promising 346% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPQnBROXRoWmlBWHBDeUVIVGZJQzg3TGJucUk4V3BuZVJtUzhYbjdFTjA4WHZ0U2ZrVmxZeDVpQlVhY0FhTnN1d2F2Q2pzNUp4UkJuSEozRUlKUnk5ZnZsdUY2dnVkNEgwM0UzTndfN1R4YjVzVDVqUW0tUDNVaWwyZ0NabE9oWUlLb2hjZzAxY01mdzUzNWpfYVU3eUZGa1QxQVpsMl9NVENJcjlJWjRZTEpCY0xNa3RVTnFUWjdwNTlDVnVXTHctem9UMlRxSFlEWGc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNazBveGw2THdkTzhKUThLWFppUkJsR1d0UUFQbEpTWEZ1cGgxZ0FGYTdjUEJZRXdVMG1ZYWdIcmlCRnV6d3EwcGtEWkI2VlM4aWQzaEFaODRXQ01Ob1dpR1J3QjBuM1QyNzJudE5xZlV4R2RpS0NydmhxUWRrV0dtVm82WVl0Wk1mYzJEREY2RElGckJxY2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQWUExdHZUN1RGMlF2TzBIajNiX2p4LW1iMEQ4YXRFc1ZZVWk2Z1dDekNyVG5FdDVvRlhHdG1jZDVydGVzcnBvckFTOV8wTGhMbmhhU09vcEtVekRCbmc3VWh0SnF0ZzB1cUd5SlBHWUYtY0NYRlh1MTBxOUpzV3g5eFlCb0xGNmpmWUtB?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPT1Y3QmRMYlhVdnY3dllncWxlQUhKUDYwbnc5alRlUENHSndBbkhBT3o1TE9wRXc0SjJLc1NoUnppYTJ5TzlvZEJDRDY0ZlJFTy0yS2xHbDk3RWdUdy1lN3dtMXNfYlR4T3Z3Qlo5THpmZmE1OFliOE9ySjZES1Qydnk2Q0JDSUE?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOYjNVbWRTQklwZ2hDbGZzMjUxYWFCeVFTVncxMXdxdXp3RVFUUWFnNXVabnJYMWRiWVplZ1g4SmhqRzNTbmtOR3dTUWxrYVJzM0ZuU25ieF9BeW9HdUM1eEdLUVNNOFJoemN6RHFJcnlXM3hwRG16YUM1WnM3M3J1cjlDRXZEbFpVV3lDUTNYY1dYSlNvZEdfdzluMVkzTkNQekx0dlRyQnoySDBTVGRMTWFQcjRSai0yMEM0aC1haVVBV1E?oc=5", "source_name": "Investing.com", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surges", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPUFNrWVJLa1lVM0RyWG1RNjNDOURHb1VHNWt5alB3TUZYaHFhTGlVQU1LZHJ3RkNtZXZNa0htYjl4UE5zeVByVEl1WFpCOFlvTUZVTzFlZ0hVZW5zcjRKOUJ3LWFPYkVKU3BDcHNOVV9HMXliZjBtU3R0T3lhQ3d4UVVGZHltT1NPZlFHZkJnSmdidjFia1BkS0pkV3RSVk13RVRGLU42WmFxY0xocllGeWl5ZFVmbXItb3FkblV3blJBRDk4T1RmakkybUZwQ2E4YkVuTkxB?oc=5", "source_name": "Investing.com", "published_at": "2025-05-06T07:00:00+00:00", "published_display": "06 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Report - Results, Call & Slides", "summary": "Heron Therapeutics (HRTX) reported strong Q1 2024 earnings, beating both EPS and revenue expectations. The company recorded an actual EPS of -$0.02 against a consensus of -$0.07, and revenue of $34.67 million, surpassing the expected $32.98 million. The report also highlights a s", "url": "https://www.tipranks.com/stocks/hrtx/earnings/q1-2024-report", "source_name": "TipRanks", "published_at": "2026-07-17T06:42:03", "published_display": "17 Jul 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of \"Hold\" from Brokerages", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQ19rV0o1LVBOUEt4VW5qS1ZzN29GWEs4NS1jbE11eVgwNW5PQ1JtQllsU21lZEFXbmNSaGdwRFd2M1RaeVZOSWlTRmZEMmFUUTdPS1EzUXVpY1ZCWkRjR0JXd1NjeHpiZ0s5S0pFWnVzUDlVX3JDMUVRLUlua0Vtb2RGeG82U0wyc0ptdlBLZU8taFZ3Vi1MSUtCSWlpdHJNTElLQnFYX1ZoUGc3ajhsc3RiYVhIcnNZN29hZXE2M1ZTSjhfZHZZQUtaLXNHRkxpQWVR?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-12T22:41:15+00:00", "published_display": "12 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics updates investors on business progress as development pipeline remains the key va", "summary": "Heron Therapeutics is progressing its drug portfolio, focusing on operational execution and a long-term strategy for treatments in oncology support and pain management. The company's stock valuation is closely tied to its clinical development pipeline, regulatory milestones, and ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-updates-investors-on-business-progress-as-development/69716306", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:24:06", "published_display": "07 Jul 2026 17:24", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HRTX - Heron Therapeutics Inc Options", "summary": "This page provides a detailed financial overview of Heron Therapeutics Inc. (HRTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider and institutional ownership, and short inter", "url": "https://finviz.com/stock?t=HRTX&p=d&ty=oc&r=y1&e=2026-07-17&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-05T15:11:34", "published_display": "05 Jul 2026 15:11", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?", "summary": "Heron Therapeutics (HRTX) faces a setback after a U.S. District Court ruled against it in Cinvanti patent litigation, leading H.C. Wainwright to lower its price target. The company plans to appeal the decision, asserting confidence in its legal arguments and intellectual property", "url": "https://www.insidermonkey.com/blog/is-heron-therapeutics-inc-hrtx-stock-a-recovery-opportunity-after-cinvanti-patent-court-ruling-1792090/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:29", "published_display": "30 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Heron Therapeutics received a notice from Nasdaq on June 25, 2026, stating that its common shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company has 180 days, until December 22, 2026, to regain compliance by maintaining a cl", "url": "https://www.tradingview.com/news/tradingview:0cc9053fbce63:0-heron-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-06-28T02:39:55", "published_display": "28 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision", "summary": "Heron Therapeutics (HRTX) has seen its analyst fair value estimate cut from US$4.75 to US$3.00 per share following a Cinvanti patent decision that invalidated claims on two patents. This revision reflects legal risks, potential generic competition for Cinvanti (which accounts for", "url": "https://finance.yahoo.com/markets/stocks/articles/heron-therapeutics-hrtx-stock-sees-230609790.html", "source_name": "Market source", "published_at": "2026-06-27T19:06:00", "published_display": "27 Jun 2026 19:06", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification", "summary": "Heron Therapeutics announced it received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement. The company has 180 calendar days, until December 23, 2024, to regain compliance, with a possible extension for another 180 days. Heron's common stoc", "url": "https://www.moomoo.com/news/post/72101837/heron-therapeutics-receives-nasdaq-minimum-bid-price-notification", "source_name": "Moomoo", "published_at": "2026-06-26T20:10:08", "published_display": "26 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P", "summary": "This article provides a statement of changes in beneficial ownership of securities for Officer Forbes William P at Heron Therapeutics. The document details the modifications in his holdings.", "url": "https://www.moomoo.com/news/notice/306995508/heron-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T09:09:01", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX)", "summary": "This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting pa", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:01", "published_display": "26 Jun 2026 07:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc Actuals & Estimates (BX:AXD2)", "summary": "This article provides an overview of Heron Therapeutics Inc. (BX:AXD2) stock, including its current price, market capitalization, analyst forecasts, and historical highs and lows. It also details the company's recent financial performance, such as earnings per share and revenue, ", "url": "https://www.tradingview.com/symbols/BX-AXD2/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-26T06:09:02", "published_display": "26 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Heron Therapeutics, Inc. \u2013 NASDAQ:HRTX", "summary": "This article provides financial data specifically regarding the enterprise value to revenue forward metric for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a stub or an entry on a financial data platform from TradingView, indicating that the value for this specific p", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:09:29", "published_display": "26 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price", "summary": "Heron Therapeutics (NASDAQ: HRTX) has received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, as its stock traded below this level for thirty consecutive days. The company has 180 calendar days, until December 22, 2026, to regain compl", "url": "https://www.stocktitan.net/sec-filings/HRTX/8-k-heron-therapeutics-inc-de-reports-material-event-6551f85a8267.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:40:23", "published_display": "25 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Heron Therapeutics, Inc. \u2013 NASDAQ:HRTX", "summary": "This article provides financial data, specifically the \"Price to sales forward\" for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial snapshot from TradingView, offering a quick look at this metric, but without further details or analysis within the provided t", "url": "https://www.tradingview.com/symbols/NASDAQ-HRTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:24", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Stock - long-term strategy under pressure after reverse split and Nasdaq warning", "summary": "Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nasdaq's minimum bid price requirements and receiving a Nasdaq listing deficiency notice. The company, focused on pain management and", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-stock-long-term-strategy-under-pressure-after-reverse/69592936", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T20:37:34", "published_display": "20 Jun 2026 20:37", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Heron Therapeutics Inc (HRTX) regarding its dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and that there is no historical data available for both dividend payments and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:35", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Heron Therapeutics Inc (HRTX) by business segment and region for the reported fiscal years, updated on April 6. It highlights that CINVANTI, SUSTOL, ZYNRELEF, and APONVIE are the primary revenue contributors, with CINVANTI ac", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:35", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting", "summary": "Heron Therapeutics (NASDAQ:HRTX) stockholders approved all six proposals at their 2026 Annual Meeting on June 11, including the election of seven directors and the ratification of their accounting firm. Key amendments to equity incentive and employee stock purchase plans were als", "url": "https://m.uk.investing.com/news/sec-filings/heron-therapeutics-stockholders-approve-director-slate-and-plan-amendments-at-annual-meeting-93CH-4731345?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-17T19:39:53", "published_display": "17 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Stock - Shareholders back equity plans and tax measure at 2026 meeting", "summary": "Heron Therapeutics shareholders approved all proposals at their 2026 annual meeting, including significant increases to equity and employee stock purchase plans and a tax benefits preservation plan. This approval provides management with greater flexibility in using stock-based c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/heron-therapeutics-stock-shareholders-back-equity-plans-and-tax-measure/69564649", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T16:10:33", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes", "summary": "Heron Therapeutics' EVP and CFO, Ira Duarte, engaged in routine equity compensation activity, exercising 12,500 restricted stock units on June 16, 2026. To cover tax obligations, Duarte disposed of 3,555 common shares at $0.38 per share. Following these transactions, Duarte direc", "url": "https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-78af11d266b6.html", "source_name": "Stock Titan", "published_at": "2026-06-17T15:10:33", "published_display": "17 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Heron Therapeutics Inc (HRTX) has a current financial score of 7.51, ranking 112 out of 388 in its industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71M, and its net profit sa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:33", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis", "summary": "Heron Therapeutics Inc (HRTX) has a current valuation score of 8.03, ranking 178 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -2.11, significantly different from its recent high and low. Data for P/B, P/S, and P/CF ratios have not been d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:08", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Heron Therapeutics Inc (HRTX), evaluating its volatility, financial risk, and investment risk. The company's risk assessment score is 4.44, ranking 80 out of 388 in the Biotechnology & Medical Research industry, with a beta of 1.62 indi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-hrtx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T21:10:08", "published_display": "16 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com", "summary": "Heron Therapeutics stockholders approved all six proposals at their 2026 Annual Meeting, including the election of seven directors and the ratification of their accounting firm. They also approved executive compensation and two plan amendments related to equity incentives and emp", "url": "https://za.investing.com/news/sec-filings/heron-therapeutics-stockholders-approve-director-slate-and-plan-amendments-at-annual-meeting-93CH-4331283", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T20:39:32", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan", "summary": "Heron Therapeutics stockholders approved several key proposals at their 2026 Annual Meeting on June 11, 2026. This included electing seven directors, ratifying their auditor, and approving executive compensation on an advisory basis. Shareholders also significantly increased the ", "url": "https://www.stocktitan.net/sec-filings/HRTX/8-k-heron-therapeutics-inc-de-reports-material-event-b902ff6de2d8.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:10:08", "published_display": "16 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)", "summary": "Heron Therapeutics faces a significant setback after a court ruled its Cinvanti patents invalid, jeopardizing its main revenue source. The growth of Zynrelef is insufficient to compensate for potential Cinvanti losses, while other products like Aponvie and Sustol have not met exp", "url": "https://seekingalpha.com/article/4913700-heron-therapeutics-in-a-tough-spot-after-cinvanti-court-loss-rating-downgrade", "source_name": "Seeking Alpha", "published_at": "2026-06-10T12:38:52", "published_display": "10 Jun 2026 12:38", "sentiment": "negative", "sentiment_pct": 5, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares", "summary": "Heron Therapeutics' EVP, William P. Forbes, exercised 12,500 restricted stock units (RSUs) into common shares on June 6, 2026, as part of his compensation, incurring no cash cost. Following this transaction, Forbes directly holds 221,611 common shares and 12,500 RSUs that will ve", "url": "https://www.stocktitan.net/sec-filings/HRTX/form-4-heron-therapeutics-inc-de-insider-trading-activity-79edca4de4e0.html", "source_name": "Stock Titan", "published_at": "2026-06-08T14:39:45", "published_display": "08 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents", "summary": "Heron Therapeutics has announced its intention to appeal a U.S. District Court ruling that invalidated patents covering its CINVANTI drug. The company will pursue this appeal to the U.S. Court of Appeals for the Federal Circuit to protect its intellectual property amidst potentia", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2293053/heron-therapeutics-appeals-ruling-invalidating-cinvanti-patents/", "source_name": "The Globe and Mail", "published_at": "2026-06-03T23:39:45", "published_display": "03 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics Says US Court Rules 2 Cinvanti Patent Claims 'Invalid'", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/heron-therapeutics-says-us-court-124355270.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:43:55+00:00", "published_display": "02 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics loses patent case over Cinvanti drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb3pjTmVJcC1LbkN5OG1qRG5ta1BCa3BBTFR3U1RCZDFnUVU2NnB5U3BiMUdVWFRWaWY0T2VWTDZGNU1CSVUzSThjdWhVcnk3aW05RmFnaFI0X29JQVRKbmRWVEYxZFVwbGE2c1NDTTItbVFNSG9mRGZMSXdiWGdQZDZkSjRWMGRvNWRxUVhXV1BiTVFoZ0JzOHpwQkF4ZXBud1VydWVUYlJCYWpOX2JxS0ZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOFRrWFZXZG5XSzJrSnJEZGZTUm92SGFyUEJ0OEhhZVVmNnhXY3VObUthZ2U3UnNMSFZYT2lpai1tVGdVYm1IR19mV283THZaaEoxMXBBa0xxUjk2RXItdmpFd21VQ0FYRTFSYVF0TGxobUtvc1I0ckp4bGplNk5NeDI3ZE9NMVFER2x1YzlWc0t2UUtOYWZ6ZEhMT1luakd1Ync?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOTWt2dXNmSW1kaXY3bjJEcmtFem9ROGFITDFrY2hDcjJrTFhET1FKWHBzRHl6bDdIcmc1Uk5PakxRbGhMeGUwVFlSOFItSGJoTXlJWkdrZzd0cktPeFdMVWpTemQxNklCbmwyYWx0aHM1SWlRenQ2dTVvSjNwTnRvdVROY1VkMDJzZzFHc1dacnJRSlluT2h0bllHWHpzZDVMS1ZjT1VB?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNbEVELTRWQTI5bmpiSDNrRnlMY0ZlX2lEOFZvT0VKOGhkSGRrSi1MNHN2N1kyVWZRQmlzYXZ2ZWN0M1h6YXhQSDU5ampwMGtIWnV3OEpOM3gwbFozLVdoMzJ5X19NSmhkLXkwRTVGdDc5dTNWam9SUGtaYjZiWTNPYlVkQTFtZ0JDcThxS1k5RWRfLTJCUnlhd3JaVlo4ZzFnZFRXZWM2RExTZFNmNEU0?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring a Promising 346% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPQnBROXRoWmlBWHBDeUVIVGZJQzg3TGJucUk4V3BuZVJtUzhYbjdFTjA4WHZ0U2ZrVmxZeDVpQlVhY0FhTnN1d2F2Q2pzNUp4UkJuSEozRUlKUnk5ZnZsdUY2dnVkNEgwM0UzTndfN1R4YjVzVDVqUW0tUDNVaWwyZ0NabE9oWUlLb2hjZzAxY01mdzUzNWpfYVU3eUZGa1QxQVpsMl9NVENJcjlJWjRZTEpCY0xNa3RVTnFUWjdwNTlDVnVXTHctem9UMlRxSFlEWGc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNazBveGw2THdkTzhKUThLWFppUkJsR1d0UUFQbEpTWEZ1cGgxZ0FGYTdjUEJZRXdVMG1ZYWdIcmlCRnV6d3EwcGtEWkI2VlM4aWQzaEFaODRXQ01Ob1dpR1J3QjBuM1QyNzJudE5xZlV4R2RpS0NydmhxUWRrV0dtVm82WVl0Wk1mYzJEREY2RElGckJxY2c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQWUExdHZUN1RGMlF2TzBIajNiX2p4LW1iMEQ4YXRFc1ZZVWk2Z1dDekNyVG5FdDVvRlhHdG1jZDVydGVzcnBvckFTOV8wTGhMbmhhU09vcEtVekRCbmc3VWh0SnF0ZzB1cUd5SlBHWUYtY0NYRlh1MTBxOUpzV3g5eFlCb0xGNmpmWUtB?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPT1Y3QmRMYlhVdnY3dllncWxlQUhKUDYwbnc5alRlUENHSndBbkhBT3o1TE9wRXc0SjJLc1NoUnppYTJ5TzlvZEJDRDY0ZlJFTy0yS2xHbDk3RWdUdy1lN3dtMXNfYlR4T3Z3Qlo5THpmZmE1OFliOE9ySjZES1Qydnk2Q0JDSUE?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOYjNVbWRTQklwZ2hDbGZzMjUxYWFCeVFTVncxMXdxdXp3RVFUUWFnNXVabnJYMWRiWVplZ1g4SmhqRzNTbmtOR3dTUWxrYVJzM0ZuU25ieF9BeW9HdUM1eEdLUVNNOFJoemN6RHFJcnlXM3hwRG16YUM1WnM3M3J1cjlDRXZEbFpVV3lDUTNYY1dYSlNvZEdfdzluMVkzTkNQekx0dlRyQnoySDBTVGRMTWFQcjRSai0yMEM0aC1haVVBV1E?oc=5", "source_name": "Investing.com", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surges", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPUFNrWVJLa1lVM0RyWG1RNjNDOURHb1VHNWt5alB3TUZYaHFhTGlVQU1LZHJ3RkNtZXZNa0htYjl4UE5zeVByVEl1WFpCOFlvTUZVTzFlZ0hVZW5zcjRKOUJ3LWFPYkVKU3BDcHNOVV9HMXliZjBtU3R0T3lhQ3d4UVVGZHltT1NPZlFHZkJnSmdidjFia1BkS0pkV3RSVk13RVRGLU42WmFxY0xocllGeWl5ZFVmbXItb3FkblV3blJBRDk4T1RmakkybUZwQ2E4YkVuTkxB?oc=5", "source_name": "Investing.com", "published_at": "2025-05-06T07:00:00+00:00", "published_display": "06 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 48, "sentiment_summary": {"positive": 6, "negative": 16, "neutral": 26, "score": 45, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 3.1, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 16}, "market_context": {"has_market_context": true, "latest_close": 0.41, "latest_week": "2026-07-10", "one_week_move": -5.5, "four_week_move": 3.6, "twelve_week_move": -58.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.76911, "market_dynamics_buy_signal": false, "relative_strength": -68.927612, "fair_value_gap": -76.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.2333, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.5% over one week, +3.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "AD HOC NEWS", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "45/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.5% over one week, +3.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Report - Results, Call & Slides"}], "updated_at": "2026-07-18T07:45:45.810781+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}